Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125407441 | 12540744 | 1 | I | 20160606 | 20160627 | 20160708 | 20160708 | EXP | NL-ELI_LILLY_AND_COMPANY-NL201606010264 | ELI LILLY AND CO | 59.00 | YR | M | Y | 0.00000 | 20160708 | CN | NL | NL |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125407441 | 12540744 | 1 | PS | Pemetrexed | PEMETREXED | 1 | Intravenous (not otherwise specified) | 500 MG/M2, CYCLICAL (1 IN 3 WEEKS) | 21462 | 500 | MG/M**2 | INJECTION | |||||||
| 125407441 | 12540744 | 2 | SS | CISPLATIN. | CISPLATIN | 1 | Intravenous (not otherwise specified) | 75 MG/M2, CYCLICAL (1 IN 3 WEEKS) | 0 | 75 | MG/M**2 | ||||||||
| 125407441 | 12540744 | 3 | C | OXAZEPAM. | OXAZEPAM | 1 | Oral | 10 MG, PRN | 0 | 10 | MG | ||||||||
| 125407441 | 12540744 | 4 | C | CARBAMAZEPINE. | CARBAMAZEPINE | 1 | Oral | 600 MG, QD | 0 | 600 | MG | QD | |||||||
| 125407441 | 12540744 | 5 | C | DICLOFENAC /00372302/ | DICLOFENAC | 1 | Oral | 75 MG, BID | 0 | 75 | MG | BID | |||||||
| 125407441 | 12540744 | 6 | C | OXYCODONE /00045603/ | OXYCODONE | 1 | Oral | 20 MG, BID | 0 | 20 | MG | BID | |||||||
| 125407441 | 12540744 | 7 | C | OXYCODONE /00045603/ | OXYCODONE | 1 | Oral | 5 MG, PRN | 0 | 5 | MG | ||||||||
| 125407441 | 12540744 | 8 | C | ROSUVASTATIN /01588602/ | ROSUVASTATIN CALCIUM | 1 | Oral | 10 MG, QD | 0 | 10 | MG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125407441 | 12540744 | 1 | Non-small cell lung cancer metastatic |
| 125407441 | 12540744 | 2 | Non-small cell lung cancer metastatic |
| 125407441 | 12540744 | 3 | Insomnia |
| 125407441 | 12540744 | 4 | Epilepsy |
| 125407441 | 12540744 | 5 | Back pain |
| 125407441 | 12540744 | 6 | Back pain |
| 125407441 | 12540744 | 8 | Hypercholesterolaemia |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125407441 | 12540744 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125407441 | 12540744 | Constipation | |
| 125407441 | 12540744 | Urinary retention |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125407441 | 12540744 | 1 | 20160422 | 0 | ||
| 125407441 | 12540744 | 2 | 20160422 | 0 | ||
| 125407441 | 12540744 | 3 | 201601 | 0 | ||
| 125407441 | 12540744 | 4 | 199912 | 0 | ||
| 125407441 | 12540744 | 5 | 2015 | 0 | ||
| 125407441 | 12540744 | 6 | 2015 | 0 | ||
| 125407441 | 12540744 | 8 | 2008 | 0 |